Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalent Launches New Business Unit
Catalent has launched a new business unit to bring new pharmaceutical and biologic products to the market. Reportedly, the new segment will build upon Catalent’s substantial expertise and
Catalent has launched a new business unit to bring new pharmaceutical and biologic products to the market. Reportedly, the new segment will build upon Catalent’s substantial expertise and
Smith & Nephew Biologics & Spine is proceeding to the next stage in the approval process for the US launch of DUROLANE Single Injection, Stabilized Hyaluronic Acid. ADVERTISEMENT
During the second quarter of 2009, Sinovac has reported sales of $20.2m, an increase of 21.2% from $16.5m in the second quarter of 2008. The gross profit for
Holzer Holzer & Fistel, has filed a class action lawsuit in the US District Court for the District of Massachusetts on behalf of purchasers of Genzyme Corporation, who
Roche and InterMune have announced dosing of first patient in a phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS
FDA has accepted the new drug application (NDA) from Strativa Pharmaceuticals, the proprietary products division of a wholly-owned subsidiary of Par Pharmaceutical, for miconazole Lauriad mucoadhesive buccal tablets
Gentium has reported top-line results from a historically controlled, multicenter, open label, phase III trial, designed to evaluate the safety and efficacy of 25mg/kg/day of Defibrotide. The study
Unichem Laboratories has received FDA approval for bisoprolol fumarate tablets, for strengths of 5mg and 10mg. Bisoprolol fumerage tablets are therapeutically equivalent to Duramed Pharmaceuticals’ Zebeta tablets. The
InterMed Discovery (IMD) has reported the acquisition of microbial Omega-3 fatty acid production strains and related know-how from the University of Saarland. Reportedly, the microbial source has the
Merck has reported that the US District Court for the District of New Jersey has ruled in it’s favor in a patent infringement suit against Teva. Teva was